New drug cocktail aims to tame tough leukemias
NCT ID NCT07604233
First seen Jun 13, 2026 · Last updated Jun 13, 2026
Summary
This study tests a combination of chemotherapy (FLAG-Ida) plus two targeted drugs (venetoclax and asciminib) in 30 adults aged 18-70 with advanced chronic myeloid leukemia or a related acute leukemia. The first part checks safety, and the second part sees if the combo helps control the disease. Participants must have a specific genetic marker (Philadelphia chromosome or BCR::ABL1).
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
UT MD Anderson
Houston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.